NHS Framework for the North of England, Branded Medicine
key details
| Value | £431,836,170 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Region | East Midlands, East of England, London, North East, North West, South East, South West, West Midlands, Yorkshire and the Humber |
| Deadline | 20 Oct 2021 |
| Contract start | 1 Mar 2022 |
| Contract end | 29 Feb 2024 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-8f156716-6a74-476b-ac41-29b32bb73599 |
Awards (31)
This procurement was awarded to 31 suppliers. Values shown are per-award; the notice total is £431,836,170.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Accord-UK Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Amgen Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| AstraZeneca shared | £238,913,892 | 7 Feb 2022 | active |
| Aventis Pharma ltd t/a Sanofi shared | £238,913,892 | 7 Feb 2022 | active |
| Bayer Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Biogen shared | £238,913,892 | 7 Feb 2022 | active |
| Bristol Myers Squibb shared | £238,913,892 | 7 Feb 2022 | active |
| Celltrion Healthcare United Kingdom Limited shared | £238,913,892 | 7 Feb 2022 | active |
| CST Pharma Limited shared | £238,913,892 | 7 Feb 2022 | active |
| Eli Lilly & Company Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Gedeon Richter UK Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Gilead Sciences Limited shared | £238,913,892 | 7 Feb 2022 | active |
| GlaxoSmithKline UK Limited shared | £238,913,892 | 7 Feb 2022 | active |
| Ipsen shared | £238,913,892 | 7 Feb 2022 | active |
| Janssen-Cilag Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Merck Serono Limited shared | £238,913,892 | 7 Feb 2022 | active |
| Merck Sharpe & Dohme (UK) Limited shared | £238,913,892 | 7 Feb 2022 | active |
| Mylan shared | £238,913,892 | 7 Feb 2022 | active |
| Napp Pharmaceuticals Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Novo Nordisk shared | £238,913,892 | 7 Feb 2022 | active |
| Organon Pharmaceuticals UK Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Pfizer Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Roche Products Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Sandoz Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Sobi (Swedish Orphan Biovitrum Ltd) shared | £238,913,892 | 7 Feb 2022 | active |
| Takeda UK Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| Teva UK Limited shared | £238,913,892 | 7 Feb 2022 | active |
| Thornton and Ross Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| UCB Pharma Ltd shared | £238,913,892 | 7 Feb 2022 | active |
| UL Global Pharma shared | £238,913,892 | 7 Feb 2022 | active |
| Zentiva Pharma UK Ltd shared | £238,913,892 | 7 Feb 2022 | active |
description
Offer reference number: CM/PHR/20/5600
CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 15 Jul 2022 | Award (award) | · | 4e1189ae-e35a-4e20-a372-9d94847b46e3-554886 |
| 8 Aug 2023 | Award (award) | · | 521ac6ee-777d-4ac4-8c5c-88045d5101fd-670252 |
more from NHS England
- Urgent Award - haematological screening · £16,202 · 29 Jul 2026
- HSCN-AWS Connectivity Service for Spine · £228,060 · 29 Jul 2026
- Incentive Voucher Provider · £60,000 · 29 Jul 2026
- CRM for NHSE participant/candidate data 26-27 · £56,640 · 28 Jul 2026
- Wayfinder and First Contact Digital Clinical Support 2026-27 · £748,000 · 23 Jul 2026
- Support Services for PPM application · £860,000 · 22 Jul 2026
- Digital Maturity Assessment · 21 Jul 2026
- Integrated Healthcare Services to Haslar Immigration Removal Centre (IRC) · £19,052,186 · 13 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.